4 news items
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial Results
ALGS
7 May 24
-dependent pharmacodynamic effects on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver
Aligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH Subjects
ALGS
3 Apr 24
, Ph.D., MBA, Chairman, President, and Chief Executive Officer at Aligos Therapeutics. "We are pleased by the engagement of the clinicians
Aligos Therapeutics Presents Clinical Data At APASL 2024 From ALG-055009 And ALG-000184 Phase 1 Studies
ALGS
27 Mar 24
lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver.
The three oral presentations provide interim data
Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies
ALGS
27 Mar 24
on atherogenic lipids and sex hormone binding globulin (SHBG), an indicator of target engagement in the liver. The three oral presentations provide interim
- Prev
- 1
- Next